INS and type 2 diabetes mellitus: Evolving treatment practices and the extending repertoire of antihyperglycemic agents in the market for type 2 diabetes have pushed insulin to even later lines of treatment because newer non-insulin antidiabetics are likely initiated before insulin (Järvinen, Laine, & Eriksson, 2016; Niskanen & Laine, 2020).